earli
success
stimul
immun
system
recogn
elimin
tumor
cell
achiev
clinic
use
cytokin
therapi
associ
immun
mediat
toxic
recombin
among
clinic
success
agent
immun
treatment
induc
long
last
complet
respons
albeit
subset
patient
melanoma
renal
cell
cancer
recent
success
immun
checkpoint
inhibitor
antibodi
therapi
cytotox
tlymphocyt
antigen
program
cell
immunotherapi
therapeut
avenu
cancer
treatment
final
emerg
mainstream
oncolog
antibodi
first
approv
us
food
drug
administr
treatment
melanoma
antibodi
inhibit
receptor
ligand
transform
treatment
paradigm
mani
solid
malign
last
twenti
year
mani
studi
demonstr
infiltr
cell
singl
import
prognost
factor
major
human
tumor
type
inhibit
alon
combin
enhanc
cell
recognit
tumor
antigen
achiev
durabl
clinic
respons
patient
melanoma
cell
specif
tumorassoci
antigen
taa
rare
blood
tumor
patient
cancer
treatment
amplifi
taaspecif
tcell
respond
patient
melanoma
combin
tcell
checkpoint
inhibitor
reveal
stun
improv
therapi
alon
patient
melanoma
receiv
combin
regimen
experienc
object
respons
therapi
efficaci
indic
tumor
high
number
somat
mutat
tumor
mutat
burden
tmb
high
tmb
increas
antigen
differ
tumour
immunolog
self
immunogen
tumor
antigen
differ
enabl
cell
recognit
may
lead
higher
number
tumor
infiltr
cell
til
opposit
scenario
immun
therapi
immun
checkpoint
inhibit
tend
poor
respons
rate
indic
patient
lower
mutat
burden
henc
addit
therapeut
approach
increas
rare
tumor
antigen
specif
cell
tumor
low
tmb
need
found
member
famili
cytokin
noncoval
homodimer
alpha
helic
cytokin
structur
similar
receptor
consist
two
molecul
alpha
chain
two
molecul
share
cytokin
express
surfac
hematopoiet
cell
includ
cell
b
cell
macrophag
identifi
factor
produc
cell
suppress
prolifer
cell
set
inhibit
secret
cytokin
helper
cell
particular
vitro
also
reduc
antigen
specif
stimul
cell
prolifer
monocyt
http
receiv
septemb
accept
octob
downregul
class
ii
major
histocompat
complex
mhcii
contrast
induc
thymocyt
prolifer
elev
express
shown
induc
cytotox
cell
mous
tumor
model
increas
express
cell
paradox
lead
increas
express
mhc
mhc
ii
defici
human
genet
mous
model
clarifi
nonredund
immunolog
properti
pathway
function
support
antiinflammatori
tumorinhibitori
function
mice
human
develop
inflammatori
bowel
diseas
ibd
cancer
preclin
tumor
model
induc
reject
tumor
predominantli
reli
cell
activ
properti
antiinflammatori
role
well
describ
mostli
engin
mous
model
defici
wherea
welldocu
stimul
tcell
cytotox
immun
respons
cancer
receiv
consider
less
attent
review
focu
mostli
use
recombin
pegyl
cytokin
abil
stimul
antigenspecif
cell
respons
applic
cancer
immun
therapi
mous
model
cancer
clinic
trial
cancer
patient
understand
antiinflammatori
mechan
earli
reveal
mous
model
endotoxemia
singl
repeat
inject
bacteri
lipopolysaccharid
lp
induc
acut
cytokin
releas
syndrom
cr
lead
vascular
shock
death
lp
activ
tolllik
receptor
pattern
recognit
receptor
prr
express
mani
myeloid
cell
prr
alert
innat
immun
system
foreign
molecul
bacteri
cell
wall
constitu
dna
damag
host
cell
stimul
prr
antigen
specif
lead
inflammatori
reaction
larg
driven
innat
immun
system
howev
lp
also
induc
inflammatori
cytokin
stimul
inflammatori
cell
induc
lp
neg
feedback
inhibit
express
share
subunit
achiev
transcript
cascad
involv
transcript
repressor
nuclear
factor
interleukin
regul
inhibit
transcript
defici
caus
microbiota
depend
coliti
due
absenc
feedback
mice
sensit
lpsinduc
shock
protect
mice
cr
also
induc
suppressor
cytokin
signal
bind
inhibit
proinflammatori
receptor
therebi
intercept
inflammatori
respons
variou
level
high
local
concentr
inflammatori
respons
prr
ligand
inject
tumor
result
suffici
local
activ
innat
immun
cell
reject
tumor
agonist
imiquimod
approv
treatment
local
basal
carcinoma
skin
tumor
reject
driven
local
activ
inflammatori
cell
macrophag
local
inflammatori
reaction
imiquimod
inde
serv
prognost
indic
treatment
success
absenc
local
inflamm
greatli
exacerb
intratumor
inject
tlr
ligand
experiment
tumor
enhanc
activ
appli
combin
neutral
antibodi
system
applic
tlr
agonist
howev
lead
lifethreaten
cr
consequ
due
limit
toxic
approach
seen
far
littl
success
system
tumor
therapi
intratumor
inject
prr
agonist
combin
inhibit
pursu
antibodi
mediat
abrog
combin
local
activ
enter
clinic
trial
expect
studi
complet
regul
proinflammatori
antiinflammatori
signal
cell
popul
crucial
mainten
normal
physiolog
well
suppress
tumor
develop
local
induc
inflamm
lead
elimin
inject
tumor
sometim
abscop
lesion
system
inflamm
appear
promot
tumor
incid
progress
chronic
inflamm
correl
tumor
incid
experiment
cancer
model
cancer
epidemiolog
develop
progress
tumor
chronic
inflam
tissu
thought
consequ
increas
compensatori
cell
prolifer
tumorpromot
microenviron
increas
angiogenesi
proteolyt
activ
increas
mutat
rate
due
releas
oxygen
radic
conspicu
absenc
tumor
immunosurveil
cytotox
cell
essenti
cytokin
homeostasi
antiinflammatori
regulatori
cell
treg
suppress
proinflammatori
cell
fig
antiinflammatori
role
earliest
demonstr
knockout
mice
spontan
develop
inflammatori
bowel
diseas
ibd
remov
commens
intestin
bacteria
antibiot
treatment
protect
mice
coliti
preval
sever
ibd
attenu
spf
facil
relev
find
confirm
patient
carri
somat
mutat
gene
spontan
develop
sever
earli
onset
ibd
importantli
presenc
increas
system
inflamm
knockout
mice
spontan
develop
colon
cancer
patient
defici
signal
develop
lymphoma
within
first
decad
life
clear
mice
develop
lymphoma
defici
patient
would
develop
colon
cancer
increas
age
differ
tumor
type
could
aris
differ
durat
inflamm
tumor
incid
antiinflammatori
medic
defici
patient
may
prevent
develop
colon
carcinoma
human
differ
microbiota
modifi
organ
specif
cancer
risk
gener
inflamm
aris
due
defici
may
provid
fertil
ground
tumor
develop
support
concept
tumorpromot
inflamm
autoinflammatori
mous
model
ablat
lead
increas
immun
patholog
mediat
proinflammatori
cell
expans
scenario
regulatori
cell
function
rate
limit
produc
essenti
recipi
cytokin
defici
treg
caus
coliti
induc
phosphoryl
treg
defici
treg
fail
expand
inflam
gut
contrast
requir
treg
mediat
suppress
tcell
prolifer
vitro
suggest
regul
inhibit
inflamm
homeostasi
treg
mice
mutat
adenomat
polyposi
coli
gene
apc
develop
intestin
tumor
driven
focal
inflamm
microbi
gut
flora
ablat
cell
increas
inflamm
increas
tumor
burden
colon
small
intestin
mice
overshoot
sever
inflamm
prevent
develop
tumor
earli
age
howev
progress
loss
cell
cellular
cytotox
led
cancer
develop
adopt
transfer
hi
cell
apc
mice
colon
tumor
lead
reduct
tumor
burden
collect
data
support
role
cell
deriv
suppress
inflamm
induc
cancer
cell
function
depend
myeloidderiv
cytokin
genet
therapeut
ablat
mice
render
resist
experiment
induc
autoinflammatori
diseas
defici
also
sever
restrict
develop
experiment
induc
tumor
accompani
defici
inflammatori
mediat
tumorpromot
inflammatori
metalloproteas
inflamm
driven
angiogenesi
simultan
tumorinfiltr
cell
cytotox
mediat
highli
preval
proinflammatori
also
suppress
nk
cell
mediat
tumor
reject
mutual
exclus
inflammatori
cytotox
immun
mediat
cell
explain
signatur
effector
cytokin
attract
activ
granulocyt
myeloid
cell
promot
angiogenesi
wound
repair
induc
antigen
present
develop
cell
immun
transcript
level
dichotomi
achiev
transcript
factor
defin
proinflammatori
cell
proinflammatori
treg
tcellspecif
delet
inhibit
inflammatori
tcell
popul
suppress
tumor
develop
apc
mice
increas
express
absenc
inflammatori
cell
cytotox
granzym
perforinposit
cell
increas
gut
indic
reciproc
regul
immun
respons
transcript
repressor
mediat
induc
inhibit
express
also
mediat
repress
intriguingli
mediat
inflammatori
signal
antiinflammatori
signal
knockout
mice
resist
experiment
uveiti
due
defici
induct
increas
cell
howev
upon
herpesviru
infect
defici
cell
less
virusspecif
cell
demonstr
depend
stimul
teff
cell
surviv
see
also
balanc
decis
cytotox
inflammatori
cell
fate
cell
also
control
tbox
transcript
factor
eomesodermin
tbet
essenti
nk
cell
cell
memori
intriguingli
compound
knockout
mice
lack
tbet
eomesodermin
cell
unabl
mount
cytotox
respons
viru
infect
instead
develop
neutrophil
mediat
wast
syndrom
driven
express
cell
proinflammatori
also
devoid
express
data
demonstr
intric
antagon
proinflammatori
signal
cellular
cytotox
import
control
cell
critic
involv
develop
tumorpromot
inflamm
intriguingli
increas
cell
activ
observ
inflammatori
respons
inhibit
ration
inflamm
control
immun
effector
modif
support
preclin
mechanist
data
clinic
correl
explor
clinic
aggress
immun
stimulatori
therapi
use
tocilizumab
control
immun
mediat
advers
event
immun
checkpoint
inhibitor
appear
clinic
safe
inhibit
antitumor
immun
function
support
concept
inflammatori
effector
cytokin
essenti
antigen
specif
tumor
immun
specif
combin
activ
antigen
specif
cell
antiinflammatori
therapi
may
provid
mean
toler
potenti
efficaci
immun
therapi
regimen
modifi
immun
respons
antigen
pattern
recognit
motiv
toward
antigen
specif
cell
specif
respons
stimul
function
cell
first
describ
bcellderiv
tcell
growth
factor
btcgf
induc
express
molecul
thymocyt
enhanc
cytotox
activ
cell
howev
also
inhibit
cell
allogen
reaction
potenti
due
natur
strength
tcr
signal
set
enhanc
prolifer
cell
direct
stimul
tcell
receptor
tcr
signal
use
monoclon
antibodi
mab
addit
induc
prolifer
cell
stimul
mab
absenc
exogen
howev
feasibl
set
mere
enhanc
respons
endogen
induc
see
cell
activ
tcr
stimul
lead
upregul
increas
sensit
tcr
stimul
cell
induct
may
select
deliv
antiapoptot
signal
tcr
stimul
cell
simultan
activ
cell
lead
temporari
induct
immun
checkpoint
receptor
activ
signatur
stabil
treatment
also
directli
induc
granzymeb
express
activ
cell
lead
higher
antigen
specif
cytotox
cell
target
cell
care
analysi
autocrin
paracrin
function
macrophag
dendrit
cell
cell
prime
show
stimul
induc
dendrit
cell
inhibit
product
monocyt
moreov
autocrin
produc
dendrit
cell
inhibit
dc
matur
prime
high
affin
antigen
lower
prime
low
affin
antigen
potenti
reduc
mhc
express
reduc
antigen
stimul
may
restrict
cell
respons
matur
immun
respons
addit
enhanc
induc
tcrindepend
prolifer
memori
cytotox
cell
select
increas
sensit
highaffin
cell
may
increas
preval
antigen
activ
ctl
convers
inhibit
may
broaden
immun
respons
reduc
antigen
restrict
could
lead
widen
cell
repertoir
expens
tcr
high
affin
select
antigen
specif
cell
isol
b
cell
lymphoma
dlbcl
increas
level
exogen
improv
surviv
activ
specif
cell
reduc
cell
apoptosi
induc
phosphoryl
express
antiapoptot
summari
stabil
activ
antigen
stimul
cell
stimul
express
cytotox
effector
molecul
fig
endogen
tumor
viru
model
protect
role
endogen
tumor
first
observ
spontan
develop
colon
carcinoma
also
mice
transgen
overexpress
antigen
present
cell
syngen
tumor
establish
normal
reject
within
week
without
treatment
depend
cell
mice
treat
chemic
carcinogen
induc
squamou
skin
tumor
develop
papilloma
carcinoma
earlier
larger
number
control
mice
mice
protect
tumor
develop
skin
carcinoma
progress
metastas
prematur
succumb
prematur
metastasi
immun
system
cancer
bear
control
mice
larg
capabl
prevent
metastasi
mice
reach
normal
age
earli
precancer
lesion
intratumor
cell
mhc
molecul
granzym
suppress
increas
mice
viral
infect
murin
hepat
b
viru
specif
cell
produc
upon
antigen
exposur
autocrin
prevent
antigen
mediat
apoptosi
increas
respons
acut
lymphocyt
choriomening
viru
lcmv
infect
endogen
suppress
cell
cell
vivo
mainten
antivir
memori
cell
requir
viral
liver
infect
inflamm
induc
produc
cell
cell
resembl
regulatori
cell
popul
produc
contribut
liver
inflamm
coronaviru
infect
cytolyticli
activ
cell
produc
reduc
cell
bystand
cell
activ
result
decreas
tissu
damag
reminisc
vitro
result
suppress
low
affin
tcr
activ
express
memori
cell
induc
syngen
tumor
model
treatment
recombin
selfrenew
memori
cell
increas
phosphoryl
respons
also
essenti
cell
expans
trypanosoma
infect
defici
affect
specif
cell
cell
respons
summari
endogen
essenti
format
potent
cell
memori
tumor
viru
challeng
enabl
high
affin
tcr
respons
suppress
bystand
cell
prolifer
antiapoptot
function
may
protect
cell
antigen
challeng
increas
express
facilit
mhc
express
antigen
recognit
potenti
also
mediat
suppress
cell
clone
weak
tcr
recognit
tumor
cell
engin
express
inject
immunocompet
host
tumor
reject
mice
reject
transplant
tumor
syngen
mous
tumor
treat
recombin
human
induc
tcelldepend
tumor
reject
tumor
vaccin
tumor
challeng
treatment
experi
applic
tumor
vaccin
enhanc
tumor
reject
treatment
human
immun
effector
phase
enhanc
tumor
reject
singl
inject
system
longliv
pegyl
version
tumorbear
mice
induc
express
granzym
tumor
infiltr
cell
sustain
treatment
led
tcelldepend
tumor
reject
varieti
rather
immun
resist
mous
tumor
model
elimin
lung
metastasi
aggress
transplant
tumor
model
strikingli
induc
reject
larg
endogen
breast
cancer
transgen
mice
particular
interest
tumor
induc
transgen
oncogen
driver
mutat
typic
harbor
reduc
frequenc
somat
mutat
therefor
increas
resist
immun
therapi
tumor
reject
induc
treatment
led
durabl
immun
memori
reject
tumor
mice
remain
resist
tumor
challeng
test
month
initi
tumor
reject
receptor
ablat
studi
indic
tumor
immun
mediat
directli
activ
intratumor
cell
express
cell
dispens
tumor
control
intratumor
cell
sustain
exposur
induc
phosphoryl
well
contrast
cell
cell
lymphoid
organ
moder
phosphoryl
fail
express
treat
mice
particularli
import
induct
induc
tbet
transcript
factor
defin
c
lineag
cell
tbet
tcractiv
transcript
factor
nfat
cooper
induc
granzym
cytotox
cell
may
suggest
observ
tumor
restrict
induct
granzym
perforin
cell
treatment
occur
presenc
tumor
antigen
mediat
tcr
stimul
also
presenc
intratumor
produc
cell
mhc
class
ii
molecul
induc
potenti
allow
increas
antigen
present
recognit
within
tumor
fig
support
concept
analysi
antigen
recognit
expans
tumor
specif
cell
syngen
mous
tumor
model
reveal
increas
number
cell
recogn
tumor
cell
tumor
isol
mhc
match
control
cell
interestingli
increas
tumor
specif
cell
observ
equal
cell
isol
tumor
blood
treat
anim
suggest
induc
tumor
reactiv
cell
circul
lymphat
blood
prolifer
tumordirect
cell
gener
thought
occur
tumordrain
lymph
node
post
prolif
cell
return
tumor
blood
stream
howev
inhibit
lymphat
migrat
inhibitor
treatment
reduc
tumor
efficaci
increas
intratumor
cell
suggest
intratumor
cell
activ
expans
suffici
induc
tumor
reject
respons
treatment
depend
intratumor
cell
expans
test
adopt
transfer
cell
tumor
bear
cell
defici
rag
mice
treatment
tumorresid
cell
rapidli
expand
within
tumor
tissu
expens
cell
carri
receptor
summari
induc
surviv
antigen
stimul
effector
effector
memori
cell
increas
cytotox
enzym
cell
deriv
mediat
upregul
antigen
present
within
tumor
fig
due
upregul
respons
antigen
recognit
treatment
select
expand
tumorresid
tumorspecif
cell
fig
defici
anim
develop
inflammatori
bowel
diseas
inflammatori
mediat
diseas
model
inhibit
treatment
genomewid
associ
studi
also
confirm
associ
variou
inflammatori
diseas
crohn
diseas
ulcer
coliti
diseas
human
genet
defici
pathway
develop
earli
onset
inflammatori
bowel
diseas
accordingli
clinic
trial
recombin
initi
nineti
intend
suppress
inflamm
chronic
inflammatori
diseas
five
thousand
individu
normal
healthi
volunt
patient
inflammatori
diseas
treat
predominantli
subcutan
inject
recombin
clinic
trial
conduct
detail
understand
molecular
cellular
mechan
antiinflammatori
function
establish
biomark
analysi
infanc
therefor
difficult
optim
treatment
moreov
pharmacolog
characterist
recombin
limit
exposur
sever
hour
subcutan
inject
diseaseassoci
proinflammatori
cytokin
reduc
significantli
indic
pharmacodynam
activ
treatment
suppress
detect
short
period
elev
serum
concentr
return
high
valu
within
h
inject
nevertheless
encourag
pegilodecakin
select
preferenti
cell
recent
antigen
encount
virtu
hi
statu
signal
lead
increas
activ
surviv
expans
taa
reactiv
cell
contrast
induc
prolifer
activ
cell
independ
tcr
signal
nk
cell
lead
activ
prolifer
larg
proport
peripher
cell
irrespect
antigen
specif
efficaci
observ
psoriasi
crohn
diseas
patient
interferon
refractori
chronic
hepat
c
reduc
liver
inflamm
fibrosi
howev
pivot
trial
frequent
use
reduc
threetimesweekli
dose
regimen
avoid
side
effect
statist
signific
diseas
modif
observ
taken
togeth
variabl
concentr
due
short
halflif
recombin
patient
may
sever
limit
therapeut
benefit
concomitantli
sign
stimul
immun
respons
observ
healthi
volunt
hladr
monocyt
elev
blood
patient
crohn
diseas
treat
daili
higher
dose
peripher
blood
mononuclear
cell
pbmc
secret
elev
level
compar
control
singl
inject
given
healthi
volunt
prior
challeng
lp
increas
granzym
b
serum
decreas
cell
increas
patient
psoriat
arthriti
result
suggest
therapeut
dose
recombin
induc
patient
key
element
reminisc
tcell
respons
includ
granzym
induct
appear
independ
sinc
induct
occur
concomitantli
suppress
summari
recombin
limit
efficaci
antiinflammatori
treatment
due
short
halflif
also
due
stimulatori
activ
cell
express
support
preclin
efficaci
pegyl
murin
advanc
tumor
model
mice
phase
studi
pegilodecakin
start
preclin
result
indic
continu
exposur
pegilodecakin
would
requir
achiev
optim
antitumor
efficaci
analysi
cellular
target
popul
mice
suggest
tumor
resid
cell
would
primari
effector
popul
necessari
therapeut
effect
indic
tumor
tissu
relev
pharmacokinet
compart
achiev
increas
system
exposur
suffici
intratumor
concentr
daili
subcutan
inject
pegyl
chosen
initi
clinic
strategi
biolog
effect
teff
cell
benefici
throughout
tumor
progress
patient
therefor
allow
continu
therapi
diseas
progress
phase
studi
enrol
patient
advanc
solid
tumor
fail
avail
prior
therapi
includ
prior
immun
therapi
ipilimumab
object
tumor
respons
measur
use
immun
relat
respons
criteria
irrc
patient
allow
interrupt
dose
brief
intermiss
unrel
relat
advers
event
could
resum
treatment
tumor
progress
dose
limit
toxic
dlt
pegilodecakin
well
toler
escal
dose
kg
result
sustain
meaning
elev
serum
concentr
ngml
sinc
half
maxim
effect
concentr
pegilodecakin
cellbas
vitro
assay
approxim
ngml
serum
concentr
cancer
patient
prior
dose
averag
pg
ml
dlt
determin
advers
event
ae
includ
anemia
thrombocytopenia
fever
fatigu
hypotens
durabl
autoimmun
relat
advers
event
record
importantli
advers
event
transient
resid
short
dose
interrupt
allow
patient
cytopenia
sustain
tumor
respons
continu
treatment
short
treatment
interrupt
sever
month
year
advers
event
profil
distinguish
pegilodecakin
therapi
sever
hypotens
dose
durat
treatment
limit
despit
wellestablish
clinic
benefit
highdos
treatment
confirm
antiinflammatori
function
immun
relat
inflammatori
advers
event
ira
coliti
pneumon
hepat
observ
differenti
treatment
also
immun
checkpoint
inhibitor
therapi
frequent
induc
ira
rare
caus
transient
cytopenia
pegilodecakin
treat
patient
system
upregul
immun
stimulatori
cytokin
reduc
concentr
immun
suppress
support
hypothesi
pharmacolog
stabil
may
increas
cell
activ
patient
see
also
chapter
immun
regul
patient
object
respons
pegilodecakin
monotherapi
observ
sever
patient
dose
escal
cohort
includ
renal
cell
cancer
patient
rcc
patient
uveal
melanoma
expans
cohort
patient
pretreat
rcc
prior
line
therapi
four
object
respons
object
respons
rate
orr
respons
durabl
sever
patient
remain
therapi
year
rcc
nivolumab
monotherapi
compar
respons
rate
phase
studi
contrast
high
dose
reserv
previous
treat
patient
expect
respons
pretreat
rcc
patient
similarli
pegyl
singl
agent
object
tumor
respons
pretreat
advanc
rcc
patient
establish
emerg
treatment
rcc
also
discuss
taken
togeth
pegilodecakin
encourag
efficaci
monotherapi
combin
chemotherapi
discuss
accept
side
effect
profil
phase
phase
studi
current
progress
introduct
immun
checkpoint
inhibitor
progress
chang
landscap
cancer
treatment
mani
indic
recent
year
antibodi
approv
fda
first
line
treatment
alon
variou
combin
treatment
melanoma
rcc
nonsmal
cell
lung
cancer
nsclc
indic
treatment
melanoma
patient
pembrolizumab
induc
object
clinic
respons
phase
clinic
respons
predominantli
observ
patient
whose
tumor
prior
therapi
strong
infiltr
cell
suggest
preexist
immun
requir
clinic
success
intriguingli
respons
correl
high
burden
somat
mutat
nsclc
patient
tumor
respons
differ
tumor
histolog
correl
gener
frequenc
somat
mutat
tumor
type
preclin
data
indic
pegilodecakin
increas
frequenc
activ
tumor
infiltr
cell
poorli
infiltr
tumor
cell
mediat
tumor
respons
also
observ
endogen
tumor
transgen
tumor
model
gener
strongli
reduc
number
somat
mutat
accordingli
low
infiltr
cell
moreov
patient
pegilodecakin
monotherapi
increas
number
activ
tumor
infiltr
cell
tumor
low
cell
infiltr
prior
therapi
cell
receptor
stimul
simultan
induc
immun
checkpoint
molecul
receptor
also
express
cell
exhaust
cell
hiv
patient
increas
express
suggest
cell
exhaust
continu
antigen
stimul
may
primari
target
therapi
rais
possibl
stimul
pathway
inhibit
may
lead
improv
clinic
respons
scenario
pegilodecakin
may
increas
number
tumor
infiltr
antigen
specif
cell
would
restor
tcr
activ
test
concept
cohort
patient
treatment
refractori
advanc
rcc
nonsmal
cell
lung
cancer
nsclc
enrol
receiv
combin
pegilodecakin
plu
one
two
inhibitori
antibodi
pembrolizumab
nivolumab
nsclc
patient
combin
pegilodecakin
plu
object
respons
rate
progress
free
surviv
pf
month
median
overal
surviv
os
nsclc
patient
pegilodecakin
plu
month
similar
popul
pembrolizumab
monotherapi
orr
pf
month
overal
surviv
os
month
respons
nsclc
correl
express
tumor
cell
tumor
express
half
tumor
cell
hi
respond
orr
tumor
express
show
respons
less
case
hi
nsclc
orr
neg
nsclc
treat
pegilodecakin
plu
object
respons
pf
month
rcc
patient
least
one
prior
therapi
prior
pegilodecakin
orr
pegilodecakin
plu
month
pf
overal
surviv
os
similar
popul
rcc
patient
receiv
nivolumab
progress
first
line
sunitinib
orr
pf
month
os
less
treatment
rcc
patient
receiv
nivolumab
ipilimumab
first
line
treatment
orr
pf
month
os
summari
combin
treatment
lung
renal
cancer
combin
pegyl
appear
provid
increas
tumor
respons
rate
also
increas
progress
free
overal
surviv
compar
either
agent
alon
patient
treat
subcutan
inject
recombin
discontinu
exposur
peak
concentr
ngml
less
ngml
h
despit
antiinflammatori
activ
immun
activ
observ
clinic
trial
includ
suppress
enhanc
lipopolysaccharid
induc
granzym
cancer
patient
treat
pegilodecakin
sustain
serum
level
immun
cytokin
profil
consist
cell
polar
cell
cytotox
domin
antiinflammatori
effect
consist
partial
suppress
contrast
cell
deriv
cytotox
effector
molecul
includ
fasl
lymphotoxinb
strongli
induc
start
increas
serum
delay
increas
day
continu
pegilodecakin
treatment
thereaft
elev
throughout
pegilodecakin
dose
period
least
sever
month
data
cancer
patient
indic
howev
level
remain
rel
low
pgml
cytokin
releas
syndrom
observ
comparison
patient
treat
iv
bolu
recombin
transient
rise
serum
pgml
patient
antibodycoupl
spike
ngml
pegilodecakin
also
induc
sustain
elev
induct
correl
directli
tumor
reduct
patient
irrc
induc
maintain
express
cell
potenti
inhibit
activ
induc
cell
death
support
import
function
cell
mediat
tumor
respons
car
cell
express
tandem
chimer
antigen
receptor
car
strongli
enhanc
efficaci
mice
recombin
studi
cancer
patient
dose
mgkg
partial
respons
observ
month
day
treatment
interv
second
studi
melanoma
rcc
patient
respons
observ
may
plausibl
key
factor
mediat
tumor
respons
repres
import
contribut
element
mediat
tumor
respons
tumor
tissu
treatment
pegilodecakin
led
increas
granzymeb
cell
upregul
mhci
tumor
tumor
infiltr
cell
similar
previous
report
data
mous
model
express
mhc
molecul
human
cancer
correl
improv
prognosi
patient
summari
pegilodecakin
induc
system
signatur
consist
polar
cell
activ
induct
cell
invigor
patient
pegilodecakin
induc
signific
chang
overal
lymphocyt
count
number
regulatori
cell
widespread
nk
cell
prolifer
contrast
therapi
use
pegyl
induc
transient
lymphopenia
follow
prolifer
expans
cell
treg
cell
nk
cell
rather
pegilodecakin
percentag
prolifer
cell
increas
peripher
blood
cell
also
increas
tumor
biopsi
treat
patient
antigen
recognit
upregul
express
immun
checkpoint
therebi
indic
activ
state
cell
howev
increas
multipl
immun
inhibitori
receptor
particular
upregul
nonprolifer
cell
indic
function
exhaust
therapi
induc
prolifer
immun
checkpoint
posit
cell
reminisc
reinvigor
exhaust
immun
checkpoint
express
cell
immun
checkpoint
inhibitor
transient
prolifer
expans
cell
observ
melanoma
patient
ratio
prolifer
tumor
burden
correl
antitumor
respons
howev
induc
invigor
transient
patient
induc
prolifer
occur
within
first
month
treatment
pegilodakin
treatment
cell
continu
expand
blood
patient
continu
treatment
expans
correl
directli
improv
tumor
respons
also
exhaust
cell
popul
increas
pegilodecakin
tcr
stimul
simultan
upregul
immun
checkpoint
express
receptor
provid
plausibl
explan
select
rescu
popul
pegilodecakin
treat
patient
increas
immun
checkpoint
posit
cell
could
reflect
increas
recent
activ
cell
potenti
consequ
increas
antigen
stimul
due
induc
mhc
express
rescu
previous
exhaust
cell
cell
receptor
tcr
sequenc
analysi
blood
patient
pegilodecakin
show
clonal
expans
cell
clone
rare
undetect
prior
treatment
expand
clone
continu
expans
throughout
analyz
treatment
period
patient
pegilodecakin
expand
contract
cell
clone
patient
object
tumor
respons
increas
number
expand
cell
clone
blood
number
expand
cell
per
patient
also
correl
directli
tumor
shrinkag
expans
newli
discover
cell
clone
expans
cell
blood
patient
reminisc
expans
tumor
specif
cell
blood
treat
tumor
model
remain
seen
pegilodecakin
inde
expand
tumor
specif
cell
popul
patient
combin
pegilodakin
pembrolizumab
appear
increas
object
tumor
respons
rate
howev
expans
prolifer
cell
expans
novel
cell
clone
blood
similar
pegilodecakin
alon
plausibl
combin
therapi
primarili
enhanc
antigen
specif
recognit
elimin
tumor
cell
within
tissu
summari
analysi
patient
treat
pegilodecakin
suggest
induc
polar
immun
system
cell
invigor
combin
studi
progress
sinc
clone
antiinflammatori
properti
cytotox
stimulatori
function
cell
studi
vitro
mous
model
patient
inhibit
immun
mediat
inflamm
show
great
promis
varieti
inflammatori
diseas
clinic
success
ultim
limit
like
due
pharmacolog
properti
recombin
use
clinic
studi
cancer
patient
element
immun
regul
encapsul
may
beneficiari
tumor
promot
polar
chronic
inflamm
induc
recruit
macrophag
neutrophil
tumor
enabl
inflamm
induc
angiogenesi
fuel
tumor
growth
metastasi
hand
reinvigor
exhaust
anerg
cell
inhibit
activ
induc
cell
death
tumor
antigen
specif
cell
may
enabl
reject
larg
tumor
sit
crossroad
immun
process
pegyl
increas
antigen
specif
cell
cytotox
antitumor
immun
respons
support
immun
stimulatori
role
higher
sustain
concentr
howev
mediat
reduct
inflammatori
pathway
also
detect
cancer
patient
induc
stimul
cell
deriv
appear
overcom
suppress
effect
mhc
express
mice
human
contrast
therapeut
modal
appear
induc
key
immunostimulatori
cytokin
cell
strictli
depend
upon
antigenstimul
tcr
signal
may
also
skew
cell
toward
clone
recogn
high
affin
antigen
exclud
bystand
clone
specif
expans
cell
reflect
recent
antigen
exposur
select
cell
clone
patient
may
support
properti
explor
antigen
specif
pegilodecakin
induc
cell
repertoir
cancer
patient
would
warrant
contrast
therapeut
stimul
inflammatori
cytokin
induc
broad
cell
stimul
system
releas
high
level
lead
system
immun
toxic
fig
inhibit
immun
checkpoint
bypass
restrict
tcr
signal
cell
impos
neg
regulatori
pathway
therebi
allow
cell
activ
lower
affin
tumor
antigen
enlist
increas
repertoir
cell
antitumor
respons
lead
enhanc
tumor
immun
may
potenti
also
explain
autoimmunerel
side
effect
checkpoint
inhibitor
combin
activ
immun
checkpoint
inhibitor
may
overcom
two
essenti
limit
immun
suppress
tumor
microenviron
repres
promis
novel
therapeut
avenu
treatment
patient
cancer
